




Contents lists available at ScienceDirect

# Biochimica et Biophysica Acta

journal homepage: [www.elsevier.com/locate/bbalip](http://www.elsevier.com/locate/bbalip)



## Hepatic fatty acid uptake is regulated by the sphingolipid acyl chain length



Woo-Jae Park<sup>a,b</sup>, Joo-Won Park<sup>a,c</sup>, Alfred H. Merrill Jr.<sup>d</sup>, Judith Storch<sup>e</sup>,  
Yael Pewzner-Jung<sup>a</sup>, Anthony H. Futerman<sup>a,\*</sup>

<sup>a</sup> Department of Biological Chemistry, Weizmann Institute of Science, Rehovot 76100, Israel

<sup>b</sup> Department of Biochemistry, School of Medicine, Gachon University, Incheon 406-799, South Korea

<sup>c</sup> Department of Biochemistry, School of Medicine, Ewha Womans University, Seoul 158-710, South Korea

<sup>d</sup> School of Biology and Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA 30332-0230, USA

<sup>e</sup> Department of Nutritional Sciences, Rutgers Center for Lipid Research, Rutgers University, New Brunswick, NJ 08901, USA

### ARTICLE INFO

#### Article history:

Received 10 April 2014

Received in revised form 8 September 2014

Accepted 11 September 2014

Available online 19 September 2014

#### Keywords:

Sphingolipid

Ceramide synthase

Fatty acid uptake

Fatty acid transport protein

Fatty acid binding protein

Cluster of differentiation 36

### ABSTRACT

Ceramide synthase 2 (CerS2) null mice cannot synthesize very-long acyl chain (C22–C24) ceramides resulting in significant alterations in the acyl chain composition of sphingolipids. We now demonstrate that hepatic triacylglycerol (TG) levels are reduced in the liver but not in the adipose tissue or skeletal muscle of the CerS2 null mouse, both before and after feeding with a high fat diet (HFD), where no weight gain was observed and large hepatic nodules appeared. Uptake of both BODIPY-palmitate and [<sup>3</sup>H]-palmitate was also abrogated in the hepatocytes and liver. The role of a number of key proteins involved in fatty acid uptake was examined, including FATP5, CD36/FAT, FABPpm and cytoplasmic FABP1. Levels of FATP5 and FABP1 were decreased in the CerS2 null mouse liver, whereas CD36/FAT levels were significantly elevated and CD36/FAT was also mislocalized upon insulin treatment. Moreover, treatment of hepatocytes with C22–C24-ceramides down-regulated CD36/FAT levels. Infection of CerS2 null mice with recombinant adeno-associated virus (rAAV)-CerS2 restored normal TG levels and corrected the mislocalization of CD36/FAT, but had no effect on the intracellular localization or levels of FATP5 or FABP1. Together, these results demonstrate that hepatic fatty acid uptake via CD36/FAT can be regulated by altering the acyl chain composition of sphingolipids.

© 2014 Elsevier B.V. All rights reserved.

### 1. Introduction

Triacylglycerols (TG) are transported in very low density lipoprotein (VLDL) particles or chylomicrons and degraded to free fatty acids (FFAs) by the action of hepatic lipase (HL). Although FFAs were thought to enter cells by diffusion, long chain fatty acid (LCFA) uptake is now believed to be, at least partially, protein-mediated, dependent on fatty acid transport proteins (FATPs), plasma membrane fatty acid binding protein (FABPpm) and fatty acid translocase (CD36/FAT) [1,2]. Six FATP family members have been identified, with each displaying tissue-specific expression [1]. An FATP5 null mouse displays reduced hepatic TG and FFA levels [3]. Upon insulin stimulation, CD36/FAT localizes from an interior vesicle population to the plasma membrane [4–7], and in the absence of caveolin-1, CD36/FAT is mis-targeted out of

detergent-resistant membranes (DRMs), resulting in reduced FFA uptake [8]. A caveolin-1 null mouse is resistant to diet-induced obesity [9], and inhibition of caveolae formation results in decreased oleic acid uptake [10].

Sphingolipids (SLs) are major components of the plasma membrane where they are involved in regulating a number of processes. The backbone of all SLs is ceramide. In mammals, ceramide is synthesized by six ceramide synthases (CerS) [11], with each using acyl CoAs of different chain lengths for *N*-acylation of the sphingoid long chain base. CerS2, which generates very-long acyl chain (VLC) ceramides (C22–24-ceramides), is the best characterized CerS, largely due to the generation and characterization of a CerS2 null mouse [12,13], which displays a wide range of pathologies, many of which are associated with the liver, where CerS2 is expressed at high levels. CerS2 null mice contain virtually no VLC-ceramides but contain elevated levels of C16-ceramide and sphinganine, which appear to be the cause of hepatopathy, hepatic insulin resistance, hepatic oxidative stress and mitochondrial dysfunction [12–15], probably due to altered membrane properties [16]. However, the pathologies are not caused by a general defect in liver function, but rather by the dysfunction of specific biochemical pathways. For instance, CerS2 null mice are insensitive to LPS/galactosamine-mediated

*Abbreviations:* CD36/FAT, fatty acid translocase; CerS, ceramide synthase; DRMs, detergent resistant membranes; FABP, fatty acid binding protein; FABPpm, plasma membrane fatty acid binding protein; FATP, fatty acid transport protein; FFA, free fatty acid; HFD, high fat diet; LCFA, long chain fatty acid; NAFLD, nonalcoholic fatty liver disease; SLs, sphingolipids; SSO, sulfo-*N*-succinimidyl oleate; TG, triacylglycerol; VLC, very-long chain

\* Corresponding author. Tel.: +972 8 9342704; fax: +972 8 9344112.

E-mail address: [tony.futerman@weizmann.ac.il](mailto:tony.futerman@weizmann.ac.il) (A.H. Futerman).

hepatic failure due to defective TNFR1 internalization [17] and to drug-induced liver injury due to dysfunctional gap junctions [18]. Thus, it is not possible to predict the outcome of manipulation of the liver due to the variety of pathways that are, or are not affected, by altering the SL acyl chain composition.

We now demonstrate that LCFA uptake is disrupted in the CerS2 null mouse liver, resulting in reduced hepatic TG accumulation even after a high fat diet (HFD). These data might implicate SL synthesis as a putative regulatory mechanism in nonalcoholic fatty liver disease (NAFLD).

## 2. Materials and methods

### 2.1. Materials

Optiprep, tyloxapol and sulfo-N-succinimidyl oleate (SSO) were from Sigma Aldrich (St Louis, MO). C16–C24 ceramides were from Avanti Polar Lipids (Alabaster, AL). The antibodies used in this study were anti-caveolin-1, anti-clathrin (Cell Signaling Technology, Beverly, MA), anti-flotillin-1, anti-IR $\beta$  (BD Biosciences, San Diego, CA), anti- $\alpha$ -tubulin, anti- $\beta$ -actin, anti-HA, anti-Flag, anti-CerS2 (Sigma Aldrich, St Louis, MO), anti-FATP5, anti-1163-phosphorylated IR $\beta$  (Santa Cruz Biotechnology, Santa Cruz, CA), anti-CD36/FAT (eBioscience, San Diego, CA), anti-GAPDH (Millipore, Temecula, CA), anti-FABPpm (Abcam, Cambridge, MA) and anti-Cy2, anti-Cy3 (Jackson ImmunoResearch Laboratories, West Grove, PA). The anti-FABP1 antibody was obtained as described [19]. [9,10- $^3$ H(N)]-triolein and [ $^{14}$ C]-palmitic acid were from the American Radiolabeled Chemicals (St Louis, MO) and [9,10-

$^3$ H (N)]-palmitic acid was from Amersham International (Amersham, UK). BODIPY-palmitate was from Invitrogen (Carlsbad, CA).

### 2.2. Animals

CerS2 null mice were generated as described [12,13]. All mice were treated according to the Animal Care Guidelines of the Weizmann Institute of Science Animal Care Committee and the National Institutes of Health's Guidelines for Animal Care.

### 2.3. Lipid extraction and thin layer chromatography


Lipids were extracted using chloroform/methanol, (2:1, vol:vol) and separated by thin layer chromatography (TLC) using heptane/isopropyl ether/acetic acid as the developing solvent (60:40:3, vol:vol:vol). TLC plates were sprayed with copper sulfate (15.6% copper sulfate, 9.4% phosphoric acid) and incubated at 100 °C for 8 min.

### 2.4. TG and FFA quantification

TGs and FFAs were measured using colorimetric assays (Triglyceride Quantification Kit, Biovision, Palo Alto, CA, and Free Fatty Acid Quantification kit, Biovision, Palo Alto, CA).

### 2.5. High fat diet

HFD (D12492) (60% fat, 20% carbohydrate, 20% protein, 5.24 kcal/g) and chow diets (D12450K) (10% fat, 70% carbohydrate, 20% protein,



**Fig. 1.** TG and FFA levels in 1–4 month-old CerS2 null mouse liver. TG levels were measured in the liver by two independent methods, (A) TLC (representative result of 3 independent experiments) and (C) a colorimetric assay ( $n = 3$ ). (B) Lipid levels in skeletal muscle and adipose tissue. (D) TG and (E) FFA levels in serum ( $n = 5–6$ ). ChE, cholesteryl ester; Ch, cholesterol; DAG, diacylglycerol. Data are means  $\pm$  S.E.M. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ .

3.85 kcal/g) were from Research Diets (New Brunswick, NJ). 2–3-month-old male mice were fed with either a HFD or chow diet for 12 weeks and had free access to water and food.

## 2.6. Glucose-tolerance test


Glucose-tolerance test was performed as described [14]. After 8-h starvation, glucose (2.0 g/Kg) was injected intraperitoneally, and blood glucose was measured using an automatic glucometer (Accu-Chek Performa, Roche Diagnostics).

## 2.7. Histology

The liver was fixed in 4% paraformaldehyde solution overnight and embedded in paraffin, sectioned at 4  $\mu$ m and stained with hematoxylin and eosin.

## 2.8. Fatty acid oxidation

Fatty acid oxidation in 2-month-old fed or fasted WT and CerS2 null mice liver was examined as described [20,21]. Briefly, 1  $\mu$ Ci of [ $^{14}$ C]-palmitate was added to a liver homogenate (1 mg of protein) and



**Fig. 2.** Effect of a HFD on CerS2 null mice. (A) Weight of 6-month-old WT and CerS2 null mice during feeding with either a chow or HFD ( $n = 8$ ). (B) Glucose tolerance test after 8-h starvation ( $n = 8$ ). (C) Size of hepatic nodules 12 weeks after feeding with a HFD. Arrows indicate hepatic nodules in three examples of CerS2 null mouse liver. Scale bar, 10 mm. (D) Hematoxylin & eosin staining of WT and CerS2 null mouse liver after feeding with a HFD. Arrows indicate hepatic nodules. Scale bar, 1 mm. (E) Liver/body mass ( $n = 4$ ). Data are means  $\pm$  S.E.M. \*\* $P < 0.01$ , \*\*\* $P < 0.001$ .

incubated with 7% perchloric acid (PCA) for 24 h at 37 °C with shaking. <sup>14</sup>CO<sub>2</sub> was captured using tissue paper soaked in 1 M of benzethonium hydroxide. Acidified samples were centrifuged at 2200 ×g<sub>av</sub> for 10 min and oxidation was calculated by summing total radioactivity of the supernatant (acid-soluble products) and of the tissue paper (CO<sub>2</sub>).


2.9. Absorption and distribution of dietary fat

Fat absorption and uptake in intestine were measured as described [22]. Briefly, 2–3-month-old mice were injected with 100 μl of tyloxapol (5% in PBS) into the tail vein and gavaged with 2 μCi of [9,10-<sup>3</sup>H(N)]-triolein in 100 μl of olive oil. Blood was collected after 1, 2 and 4 h and

radioactivity was measured. For the distribution of dietary fat, mice were fasted for 6 h and subsequently gavaged with 1 μCi of [9,10-<sup>3</sup>H(N)]-triolein in 100 μl of olive oil. After 2 h, the small intestine was excised and cut into 2-cm pieces. Radioactivity was analyzed with Ultima Gold scintillation cocktail (PerkinElmer Life and Analytical Sciences, Boston, MA).


2.10. Triglyceride hydrolase, MGAT and DGAT activity assays

TG hydrolase [23,24], MGAT and DGAT assays in 2-month-old WT and CerS2 null mice were performed as described [25].



**Fig. 3.** Hepatic TG levels after feeding with a HFD. TG levels were measured in the liver from 6-month-old mice by two independent methods, (A) TLC (representative result of 3 independent experiments) and (B) a colorimetric assay (n = 3). (C) Hematoxylin & eosin staining. The nodule is from a CerS2 null mouse. Scale bar, 100 μm. (D) Serum TG and (E) FFA levels (n = 3). ChE, cholesterol ester; Ch, cholesterol; DAG, diacylglycerol. Data are means ± S.E.M. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.





**Fig. 4.** Intestinal TG absorption and hepatic fatty acid oxidation. (A) Distribution of [ $^3\text{H}$ ]-Triolein in 2-month-old CerS2 null mouse intestine ( $n = 3$ ). (B) Plasma radioactivity after administration of tyloxapol and [ $^3\text{H}$ ]-Triolein ( $n = 3$ ). (C) Fatty acid oxidation in 2–3-month-old WT and CerS2 null mice liver ( $n = 4$ ). \* $P < 0.05$ , \*\*\* $P < 0.001$ .

### 2.11. Hepatocyte isolation and lipid or insulin treatment


Hepatocytes were isolated as described [14] from 2-month-old mice. After 18-h starvation, BODIPY-palmitate (20  $\mu\text{M}$ ) was added to serum-free media with 0.1% FA-free bovine serum albumin (Sigma Aldrich, St Louis, MO) (the molar ratio of BODIPY-palmitate/BSA was 1.3) and incubated for various times. Hepatocytes were fixed, stained by Hoechst 33342 (Invitrogen, Carlsbad, CA) and examined by confocal laser scanning microscopy using an Olympus Fluoview FV500 imaging system. BODIPY-palmitate and Hoechst 33342 were detected with excitation wavelengths of 492 and 405 nm, respectively. Hepatocytes, permeabilized with 20  $\mu\text{g/ml}$  of digitonin for 10 min every 6 h, were incubated for 24 h with 10  $\mu\text{M}$  of C16–C24 ceramides. In some cases, hepatocytes were treated with insulin (80 IU/l for 4 h, 10 nM for 0.5 h, or 100 nM for 0.5 h).

### 2.12. [9,10 $N$ - $^3\text{H}$ ]-palmitic acid uptake


6.6 mCi/kg of [9,10  $N$ - $^3\text{H}$ ] palmitic acid (dried under  $\text{N}_2$  and dissolved in saline with 5 mg/ml of FA-free bovine serum albumin (the molar ratio of [9,10  $N$ - $^3\text{H}$ ] palmitate/BSA was 0.5)) was injected via the tail vein. Thirty minutes after injection, mice were euthanized and radioactivity quantified.

### 2.13. Real time PCR, cell culture and transfection

Real Time PCR, cell culture and transfection were performed as described [14]. Primers for real time PCR are listed in Supplemental Table 1.



**Fig. 5.** FFA uptake in CerS2 null mouse liver. (A) BODIPY-palmitate (green) uptake into hepatocytes isolated from 2 to 3-month-old WT and CerS2 null mice. Nuclei were labeled with DAPI (blue). This experiment was repeated 4 times with similar results. Scale bar, 20  $\mu\text{m}$ . (B) [9,10- $^3\text{H}$ (N)]-palmitate uptake into mouse tissues upon its injection into the tail vein ( $n = 4$ ). Data are means  $\pm$  S.E.M. \* $P < 0.05$ , \*\* $P < 0.01$ .



**Fig. 6.** Expression of proteins involved in hepatic FFA uptake. (A) mRNA expression in 2-month-old WT and CerS2 null mice ( $n = 3$ ). Data show as fold-change versus WT and are means  $\pm$  S.E.M. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ . FATP5, fatty acid transport protein 5; FSP27, fat specific protein 27; FABP1, fatty acid binding protein 1; FABPpm, plasma membrane fatty acid binding protein. (B) Western blots of homogenates from 2-month-old WT and CerS2 null mouse liver. Western blots of Hep3b cells after transfection with either (C) siRNA to CerS2, (D) CerS5 or (E) CerS6. Western blots were repeated at least 3 times and gave similar results.

#### 2.14. Western blotting

Radioimmunoprecipitation assay (RIPA) buffer (50 mM of Tris-Cl, pH 7.5, 150 mM of NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS and protease inhibitors) was added to liver tissue or to isolated hepatocytes and homogenized. Protein was quantified using the BCA Protein Assay Kit (Pierce Chemical Co., Rockford, IL). Fifty micrograms of protein was loaded in each lane and separated by 8–15% SDS-PAGE and transferred to nitrocellulose membranes. Membranes were blocked using 5% bovine serum albumin (BSA) in PBST (PBS with 0.1% Tween-20) and primary and secondary antibodies in PBST were added. Chemiluminescence was performed using a SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific Inc., Waltham, MA).

#### 2.15. Isolation of detergent-resistant membranes

The mouse liver was excised and homogenized at 4 °C with lysis buffer (0.1% Triton X-100, 100 mM of NaCl, 2 mM of EDTA, 2 mM of

EGTA, 30 mM of HEPES, pH 7.5, 1 mM of  $\text{Na}_3\text{VO}_4$ , 50  $\mu\text{m}$  of phenylarsine oxide and protease inhibitors). Homogenates were centrifuged (3 min,  $400 \times g_{av}$ , 4 °C) and 40% Optiprep and 10% sucrose (final concentration) were added to the supernatant, which was overlaid with 35%, 30%, 25%, 20% and 0% Optiprep containing 10% sucrose and centrifuged (6 h,  $170,000 \times g_{av}$ , 4 °C). Nine fractions were separated and kept at  $-20$  °C.

#### 2.16. Immunocytochemistry

Hepatocytes either before or after insulin treatment were fixed with 3% paraformaldehyde for 10 min and permeabilized with 0.1% saponin. Hepatocytes were blocked with 20% horse serum in PBS for 2 h and incubated with an anti-CD36/FAT antibody (1:100) or with an anti-FATP5 antibody (1:200) at 4 °C overnight. After three washes with PBS, anti-Cy2 (1:250) or anti-Cy3 antibodies (1:500) were added for 1 h. Hoechst 33342 (Invitrogen, Carlsbad, CA) was used to label nuclei, and hepatocytes were examined by confocal laser scanning microscopy. Hoechst

33342, Cy2 and Cy3 were viewed with excitation wavelengths of 405, 492 and 568 nm, respectively.

### 2.17. Separation of membrane and cytoplasmic fractions

Hepatocytes were lysed in fractionation buffer (250 mM of sucrose, 20 mM of HEPES, pH 7.4, 10 mM of KCl, 1.5 mM of MgCl<sub>2</sub>, 1 mM of EDTA, 1 mM of EGTA) containing protease inhibitors. Lysates were passed through a 25 G needle 15 times. After 15 min incubation on ice, lysates were centrifuged (5 min, 720 ×g<sub>av</sub>, 4 °C) and the pellet (the nuclear fraction) was removed. The supernatant was centrifuged (20 min, 10,000 ×g<sub>av</sub>, 4 °C) and the pellet (mitochondrial fraction) was removed. Further centrifugation of the supernatant (1 h, 100,000 ×g<sub>av</sub>, 4 °C) yielded the membrane and cytosolic fractions.

### 2.18. Recombinant AAV production

Recombinant adeno-associated virus (rAAV) containing full-length human CerS2 cDNA was produced as described [18].

### 2.19. Mass spectrometry

Electrospray ionization tandem mass spectrometry was performed using a PE-Sciex API 3000 triple quadrupole mass spectrometer and an ABI 4000 quadrupole-linear ion trap mass spectrometer [26,27].

### 2.20. Statistical analysis

Values are expressed as means ± S.E.M. Statistical significance was calculated using a Student's *t*-test.


## 3. Results

### 3.1. Reduced TG levels in the CerS2 null mouse liver

We first analyzed TG levels in CerS2 null mice, which were significantly lower in 2 and 4-month-old CerS2 null mice liver than in wild type (WT) littermate controls (Fig. 1A, C), but were unaltered in the skeletal muscle and in the adipose tissue (Fig. 1B). No differences in TG levels were detected in serum, although FFA levels were somewhat elevated in CerS2 null mice (Fig. 1D, E).

On a low fat chow diet, CerS2 null mice gained less weight than WT mice (Fig. 2A). Upon feeding with a high fat diet (HFD) for 12 weeks, WT mice showed a significant gain in body weight, as expected, whereas CerS2 null mice showed a small weight gain between 1 and 4 weeks of HFD, but weight loss after 7 weeks (Fig. 2A). The increased insulin resistance observed in CerS2 null mice [14] did not change upon feeding with the HFD (Fig. 2B). CerS2 null mice also showed dramatically enlarged liver nodules (Fig. 2C), which might be related to the enhanced levels of regenerative nodules in older, chow-fed CerS2 null mice [13], whereas the liver of WT mice fed with a HFD displayed a typical pattern of fat accumulation (Fig. 2C). Similar results were obtained using hematoxylin and eosin staining (Fig. 2D). CerS2 null mice showed an increase in liver weight upon feeding with a HFD (Fig. 2E).

While the HFD caused a huge increase in hepatic TG content in WT mice, a much smaller increase was observed in CerS2 null mice (Fig. 3A, B). Hematoxylin & eosin staining was consistent with the lack of lipid droplet accumulation in CerS2 null mice (Fig. 3C). After the HFD, the amount of TG in nodules was much lower than that in WT mice (Fig. 3A, B). Serum TG levels were elevated in CerS2 null mice (Fig. 3D), although FFA levels did not increase further after the HFD (Fig. 3E).



**Fig. 7.** Effects of VLC-ceramides on CD36/FAT expression. Hepatocytes from 2-month-old mice were treated with various acyl chain length ceramides. (A) mRNA expression levels of PPAR-γ and CD36/FAT (n = 3). (B) Protein level of CD36/FAT. Western blots were repeated at least 3 times and gave similar results. (C) Protein level of CD36/FAT in 2-month-old CerS2 null hepatocyte after C24-ceramide treatment. Western blots were repeated at least 3 times and gave similar results. Data are means ± S.E.M., \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.

### 3.2. Intestinal TG absorption and hepatic fatty acid oxidation

The lack of TG accumulation in the CerS2 null mouse liver could, in principle, be explained by altered TG uptake in the intestine, a tissue in which CerS2 is expressed at high levels [28]. However, no difference in TG (Triolein [ $9,10\text{-}^3\text{H}(\text{N})$ ]) absorption was observed between WT and CerS2 null mice (Fig. 4A). Likewise, the rate of appearance of radioactive TG in the blood was unaffected (Fig. 4B). Monoacylglycerol acyltransferase (MGAT) and diacylglycerol acyltransferase (DGAT) activities were measured in liver microsomal fractions since the sphingoid long chain base, sphingosine, has been shown to inhibit MGAT activity [29]. MGAT ( $13.6 \pm 1.3$  nmol/mg/min in WT versus  $17.1 \pm 2.6$  in CerS2 null ( $n = 4$ )) and DGAT ( $6.9 \pm 0.2$  nmol/mg/min in WT versus  $5.6 \pm 0.4$  in CerS2 null ( $n = 4$ )) activities were unaltered, as was the activity of TG hydrolase ( $103 \pm 10.8$  nmol/mg/h in WT versus  $108 \pm 9.7$  in CerS2 null ( $n = 3$ )). Interestingly, reduced levels of fatty acid oxidation were detected in both fed and fasted CerS2 null mice (Fig. 4C).


### 3.3. Fatty acid uptake is abrogated in the CerS2 null mouse liver

We next determined the relationship between liver TG levels and the rate of FFA uptake. BODIPY-palmitate uptake was dramatically

reduced in the CerS2 null mice hepatocytes (Fig. 5A), as was uptake of [ $9,10\text{-}^3\text{H}(\text{N})$ ]-palmitate upon its injection into the tail vein; [ $9,10\text{-}^3\text{H}(\text{N})$ ]-palmitate uptake was unaffected in a number of other tissues, and slightly increased in the kidney and in the adipose tissue (Fig. 5B). These data suggest that the lower levels of TG accumulation in CerS2 null mouse liver could be due to defective fatty acid uptake.

We next measured the levels of a number of key proteins involved in hepatic FFA uptake, including FATP5, CD36/FAT, FABPpm and FABP1 [1–3,30]. mRNA expression levels of PPAR- $\gamma$ , CD36/FAT, lipoprotein lipase (LPL), fat specific protein 27 (FSP27) and caveolin-2 were significantly increased in the livers of 2-month-old CerS2 null mice, whereas FATP5 and FABP1 levels were down-regulated (Fig. 6A). mRNA expression levels of hepatic lipase and FABPpm were unaltered (Fig. 6A). Western blotting was consistent with mRNA expression, since CD36/FAT levels were elevated whereas FATP5 and FABP1 levels were reduced in the 2-month-old mouse liver (Fig. 6B). FABPpm levels were unchanged (Fig. 6B).

To determine the role of specific SLs in regulating levels of these proteins, Hep3b liver cells were transfected with CerS2 siRNA [28]; in CerS2 null mice, C16-ceramide and sphinganine levels are elevated in addition to the reduced levels of VLC-ceramides [12]. Consistent with the results in the CerS2 null mouse liver, FATP5 and FABP1 levels were reduced,



**Fig. 8.** Distribution of CD36/FAT and FATP5 in DRM fractions. DRM fractions from 2-month-old (A) WT and (B) CerS2 null mouse liver analyzed by Western blotting. The experiment was repeated at least 3 times and gave similar results. (C) Intracellular location of CD36/FAT and FATP5 in hepatocytes isolated from 2-month-old WT and CerS2 null mouse after treatment with 80 mU/l insulin. Scale bar, 20  $\mu\text{m}$ . This experiment was repeated 4 times with similar results. (D) Subcellular fractionation of CD36/FAT in hepatocytes from 2-month-old WT and CerS2 null mice upon insulin treatment. This experiment was repeated 3 times with similar results. Cyt, cytoplasmic fraction; Mem, membrane fraction.



although CD36/FAT and caveolin-1 were unaltered (Fig. 6C). Transfection with CerS2 siRNA elevates C16-SL levels but only causes a small decrease in VLC-SLs [28,31], implying that the decrease in FATP5 and FABP1 levels is due to increased C16-SLs [12]. This was verified by transfecting Hep3b cells with CerS5 or CerS6. In the case of CerS5, C16-ceramide levels were elevated from  $317 \pm 70$  pmol/mg dry weight in non-transfected cells to  $986 \pm 187$  pmol/mg dry weight, and in the case of CerS6, C16-ceramide levels increased to  $835 \pm 123$  pmol/mg dry weight. CerS5 transfection led to reduced FATP5 and caveolin-1 levels (Fig. 6D), whereas CerS6 transfection led to reduced FABP1 levels (Fig. 6E). These data indicate that elevated C16-SLs levels might be responsible for the reduction in FATP5 and FABP1 levels. In contrast, the increase in CD36/FAT and PPAR- $\gamma$  expression could be regulated by additional factors. This was supported by experiments in which hepatocytes were directly incubated with VLC-ceramides. After gentle permeabilization of WT hepatocytes [32,33], PPAR- $\gamma$  and CD36/FAT levels were reduced upon incubation with C22- and C24-ceramides (Fig. 7A, B), and CD36/FAT levels were decreased upon the incubation of CerS2 null mice hepatocytes with C24-ceramide (Fig. 7C). No other ceramides, including C16-, C18- and C20-ceramides had any effect.

CD36/FAT and caveolin play a critical role in LCFA uptake, and both proteins can be isolated in DRM fractions [8,10]. CD36/FAT was mislocalized out of DRMs isolated from CerS2 null mice, where it was found in lower density fractions, as were a number of other proteins including flotillin-1 [14],  $\alpha$ -tubulin and  $\beta$ -actin (Fig. 8A and B). The distribution of FATP5 was unaltered (Fig. 8A and B), although its levels were significantly decreased (Fig. 6B). In hepatocytes isolated from WT mice, CD36/FAT translocated to the plasma membrane upon insulin treatment [4–7], but did not translocate in hepatocytes from CerS2 null mice (Fig. 8C). Translocation of CD36/FAT was also observed in membrane fractions in which CD36/FAT translocated to the membrane fraction upon insulin treatment in hepatocytes derived from WT but not from CerS2 null mice (Fig. 8D). To determine whether the changes in CD36/FAT localization might be due to insulin resistance [14],

hepatocytes were treated with high levels of insulin (100 nM), which is able to overcome the insulin resistance (Fig. 9A) but had no effect on CD36/FAT translocation in hepatocytes from CerS2 null mice (Fig. 9B).

#### 3.4. Infection of CerS2 null mice with rAAV-CerS2 restores TG levels and FFA uptake

To demonstrate a direct mechanistic association between CerS2 and CD36/FAT, mice were infected with recombinant adeno-associated virus expressing human CerS2 (rAAV-CerS2) [18]. Six to seven weeks after infection, CerS2 levels increased to ~25% of those found in WT mice (Fig. 10A, B), with a concomitant decrease in CD36/FAT levels, but no effect on FABP1 and FATP5 levels (Fig. 10A, B). Importantly, both TG levels in the liver (Fig. 10C, D) and BODIPY-palmitate uptake in hepatocytes (Fig. 10E) were restored to levels similar to those in WT mice, as was the distribution of proteins in DRMs (Fig. 11B). BODIPY-palmitate uptake in the CerS2 null hepatocyte was inhibited by sulfo-N-succinimidyl oleate (SSO) (Fig. 10E), a specific CD36/FAT inhibitor [34,35]. CD36/FAT was also re-targeted to the plasma membrane upon insulin treatment (Fig. 11C). These results demonstrate that the levels and intracellular distribution of CD36/FAT can be directly regulated by VLC-SLs, which in turn directly impacts hepatic FFA transport and TG levels.

#### 4. Discussion

The main result of the current study is that hepatic TG levels are significantly reduced in CerS2 null mice and do not increase upon feeding with a HFD. The major mechanistic explanation for this phenomenon is the altered intracellular localization of CD36/FAT, which directly impacts hepatic FFA uptake and TG accumulation in CerS2 null mice. Direct evidence for a role of CD36/FAT was obtained upon infection with rAAV-CerS2, which re-targeted CD36/FAT to the plasma membrane and





Fig. 9. Impaired CD36/FAT translocation is not due to hepatic insulin resistance. (A) Phosphorylation of insulin receptor  $\beta$  and (B) CD36/FAT translocation of hepatocytes isolated from 2-month-old WT, CerS2 null mice upon 10-nM or 100-nM insulin treatment. Scale bar, 20  $\mu$ m. This experiment was repeated 4 times with similar results.




**Fig. 10.** Effect of rAAV-CerS2 infection on protein levels and on FFA uptake. rAAV-GFP and rAAV-CerS2 were injected via the tail vein to 6–7-week-old WT and CerS2 null mice. (A) Protein expression analyzed by Western blotting. This experiment was repeated 3 times with similar results. (B) Quantification of CerS2 and CD36/FAT levels ( $n = 3$ ). Data are means  $\pm$  S.E.M. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ . (C) TG and lipid levels. This experiment was repeated 3 times with similar results. (D) Quantification of TG levels. Data are means  $\pm$  S.E.M. \* $P < 0.05$ . ( $n = 3$ ) (E) Uptake of BODIPY-palmitate into hepatocytes isolated from WT and CerS2 null mice. This experiment was repeated twice with similar results. Scale bar, 20  $\mu$ m.

restored FFA uptake, but had no effect on other proteins such as FATP5 and FABP1. Our data are consistent with the idea that hepatic CD36/FAT expression is regulated by C22–C24-ceramide levels [36]. Feeding with a HFD decreases C24-ceramide levels in the mouse liver [37,38] and increases hepatic CD36/FAT expression [39]. Thus, CerS2 appears to play an important role in the regulation of hepatic CD36/FAT expression.

The role of CD36/FAT in hepatic fatty acid uptake is somewhat controversial. Although CD36/FAT does not play a major role in fatty acid uptake in normal liver [40,41], increased hepatic CD36/FAT expression has been observed in various pathologic conditions such as cancer, NAFLD, and type 2 diabetes mellitus [42,43]. Similarly, CD36/FAT levels were up-regulated in CerS2 null mice, although CD36/FAT was non-functional since it was mis-localized, likely due to altered membrane properties [12,14,16]. Furthermore, FFA uptake via FATP5 and FABP1,

both of which are involved in FFA uptake in normal liver, seem to play a limited role in FFA uptake in CerS2 null mice due to their diminished expression. CD36/FAT was found in low density, detergent-soluble fractions in CerS2 null mice, consistent with data showing the inhibition of FA uptake in adipocytes upon methyl- $\beta$ -cyclodextrin treatment and upon transfection with a dominant-negative caveolin mutant [1,44]. Similarly, caveolin-1 null mice were resistant to diet-induced obesity [9] and CD36/FAT was isolated in detergent-soluble fractions in caveolin-1 knockout fibroblasts [8]. Thus, even though CD36/FAT levels were up-regulated, this up-regulation did not have any impact upon FFA uptake since CD36/FAT was localized intracellularly rather than at the plasma membrane upon insulin treatment. In principle, the disrupted insulin receptor signaling in CerS2 null mice [14] could play a role in the mislocalization of CD36/FAT. However, upon treatment



**Fig. 11.** Effect of rAAV-CerS2 infection on distribution of CD36/FAT and FATP5. DRM fractions from 4-month-old CerS2 null mouse liver infected with either (A) rAAV-GFP or (B) rAAV-CerS2 analyzed by Western blotting. The experiment was repeated at least 3 times and gave similar results. The location of DRMs is indicated. (C) Intracellular location of CD36/FAT upon treatment with 80 mU/l insulin of hepatocytes isolated from 4-month-old WT, CerS2 null and CerS2 null mouse liver after rAAV-CerS2 infection. Scale bar, 20  $\mu$ m. This experiment was repeated 3 times with similar results.

with high levels of insulin, resulting in normal insulin receptor phosphorylation in CerS2 null mice, CD36/FAT was not localized to the plasma membrane. In contrast, rAAV-CerS2 infection did permit CD36/FAT translocation to the plasma membrane and restored FFA uptake. Hence, the recent interest in manipulating CD36/FAT levels as a potential therapeutic target in fatty liver diseases [39] should take into account that the correct intracellular localization of CD36/FAT is critical for its proper function.

The previous studies have shown that CD36/FAT over-expression increases hepatic TG storage by increasing FFA uptake [42], and that hepatic CD36/FAT expression is regulated by LXR (liver X receptor), PXR (pregnane X receptor) and PPAR- $\gamma$  [45]. CD36/FAT is expressed mainly in the adipose tissue, skeletal muscle and heart, with relatively low expression in the liver [46]. Moreover, CD36/FAT null mice exhibit elevated plasma FFA and TG levels and impaired LPL-mediated TG clearance [47]. There are, however, significant differences in the phenotypes of CD36/FAT and of CerS2 null mice, since CD36/FAT function in the heart, skeletal muscle and adipose tissue in CerS2 null mice is unaffected, probably due to the less dramatic changes in the SL chain length in these tissues due to lower basal expression levels of CerS2.

Although CD36/FAT appears to play a major role in reduced levels of FFA uptake, other factors may also contribute, such as  $\beta$ -oxidation, lipogenesis and lipoprotein secretion. Indeed, a significant reduction in  $\beta$ -oxidation was observed in CerS2 null mice, consistent with impaired mitochondrial function in these mice [15], but demonstrating that

altered  $\beta$ -oxidation cannot explain the reduced TG levels. MGAT and DGAT activities were also unaltered.

An unexpected observation in the current study was the appearance of hepatic nodules upon feeding a HFD to CerS2 null mice, which was accompanied by lipid droplet accumulation. The mechanism of focal fatty changes is unknown, but focal tissue hypoxia might be involved [48] as might decrease blood perfusion [49]. Levels of apoptosis and proliferation are both increased in the CerS2 null mouse liver, a number of cell cycle-related genes are up-regulated [13], the liver/body weight ratio increases, and 20% of CerS2 null mice develop hepatocellular carcinoma after 14 months of age [13]. In addition, sphingosine and sphinganine are elevated in the CerS2 null mice liver although levels of sphingosine 1-phosphate and sphinganine 1-phosphate are unaltered [12]. Elevation of sphingoid bases has been reported in hepatic nodules induced by the CerS inhibitor, fumonisin B1, and by 2-acetylaminofluorene (upon partial hepatectomy) [50]. Long term treatment with fumonisin B1 has also been shown to induce hyperplastic nodules [51]. Thus, enhanced rates of proliferation, which induce chronic hypoxia or changed levels of sphingoid long chain bases, might contribute to the development of focal fatty changes.

In summary, the current study might implicate SL synthesis and turnover as a putative regulatory mechanism in NAFLD. Since NAFLD is emerging as a risk factor in diabetes and cardiovascular disease [52], our data further imply that regulating the SL acyl chain length might be of vital importance in regulating a number of other diseases of lipid metabolism and transport.



Supplementary data to this article can be found online at <http://dx.doi.org/10.1016/j.bbaliip.2014.09.009>.

## Acknowledgements

We thank Drs. Elad L. Laviad and Seung-Hoon Yang (Weizmann Institute of Science) and Dr. Sung-Chul Jung (Ewha Womans University) for their technical assistance, and Jessica R. Bame (Georgia Institute of Technology) for the measurement of sphingolipids. This work was supported by the Minerva Foundation and the Israel Science Foundation (0888/11). W.-J.P. and J.-W.P. were supported by the National Research Foundation of Korea Grant funded by the Korean Government (Ministry of Education, Science and Technology) [NRF-2013R1A1A1076013 and NRF-2013K2A1A2053119].

## References

- [1] J. Pohl, A. Ring, R. Ehehalt, T. Herrmann, W. Stremmel, New concepts of cellular fatty acid uptake: role of fatty acid transport proteins and of caveolae, *Proc. Nutr. Soc.* 63 (2004) 259–262, <http://dx.doi.org/10.1079/PNS2004341>.
- [2] N. Abumrad, C. Coburn, A. Ibrahim, Membrane proteins implicated in long-chain fatty acid uptake by mammalian cells: CD36, FATP and FABPm, *Biochim. Biophys. Acta* 1441 (1999) 4–13.
- [3] H. Doege, R.A. Baillie, A.M. Ortegon, B. Tsang, Q. Wu, S. Punreddy, et al., Targeted deletion of FATP5 reveals multiple functions in liver metabolism: alterations in hepatic lipid homeostasis, *Gastroenterology* 130 (2006) 1245–1258, <http://dx.doi.org/10.1053/j.gastro.2006.02.006>.
- [4] M.M. van Oort, J.M. van Doorn, A. Bonen, J.F.C. Glatz, D.J. van der Horst, K.W. Rodenburg, et al., Insulin-induced translocation of CD36 to the plasma membrane is reversible and shows similarity to that of GLUT4, *Biochim. Biophys. Acta* 1781 (2008) 61–71, <http://dx.doi.org/10.1016/j.bbaliip.2007.11.006>.
- [5] J.J.F.P. Luiken, D.P.Y. Koonen, J. Willems, A. Zorzano, C. Becker, Y. Fischer, et al., Insulin stimulates long-chain fatty acid utilization by rat cardiac myocytes through cellular redistribution of FAT/CD36, *Diabetes* 51 (2002) 3113–3119.
- [6] J.J.F.P. Luiken, D.J. Dyck, X.X. Han, N.N. Tandon, Y. Arumugam, J.F.C. Glatz, et al., Insulin induces the translocation of the fatty acid transporter FAT/CD36 to the plasma membrane, *Am. J. Physiol. Endocrinol. Metab.* 282 (2002) E491–E495, <http://dx.doi.org/10.1152/ajpendo.00419.2001>.
- [7] X. Buqué, A. Cano, M.E. Miquílana-Colina, C. García-Monzón, B. Ochoa, P. Aspichueta, High insulin levels are required for FAT/CD36 plasma membrane translocation and enhanced fatty acid uptake in obese Zucker rat hepatocytes, *Am. J. Physiol. Endocrinol. Metab.* 303 (2012) E504–E514, <http://dx.doi.org/10.1152/ajpendo.00653.2011>.
- [8] A. Ring, S. Le Lay, J. Pohl, P. Verkade, W. Stremmel, Caveolin-1 is required for fatty acid translocase (FAT/CD36) localization and function at the plasma membrane of mouse embryonic fibroblasts, *Biochim. Biophys. Acta* 1761 (2006) 416–423, <http://dx.doi.org/10.1016/j.bbaliip.2006.03.016>.
- [9] B. Razani, T.P. Combs, X.B. Wang, P.G. Frank, D.S. Park, R.G. Russell, et al., Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities, *J. Biol. Chem.* 277 (2002) 8635–8647, <http://dx.doi.org/10.1074/jbc.M110970200>.
- [10] J. Pohl, A. Ring, W. Stremmel, Uptake of long-chain fatty acids in HepG2 cells involves caveolae: analysis of a novel pathway, *J. Lipid Res.* 43 (2002) 1390–1399, <http://dx.doi.org/10.1194/jlr.M100404-JLR200>.
- [11] M. Levy, A.H. Futerman, Mammalian ceramide synthases, *IUBMB Life* 62 (2010) 347–356, <http://dx.doi.org/10.1002/iub.319>.
- [12] Y. Pewzner-Jung, H. Park, E.L. Laviad, L.C. Silva, S. Lahiri, J. Stiban, et al., A critical role for ceramide synthase 2 in liver homeostasis: I. alterations in lipid metabolic pathways, *J. Biol. Chem.* 285 (2010) 10902–10910, <http://dx.doi.org/10.1074/jbc.M109.077594>.
- [13] Y. Pewzner-Jung, O. Brenner, S. Braun, E.L. Laviad, S. Ben-Dor, E. Feldmesser, et al., A critical role for ceramide synthase 2 in liver homeostasis: II. insights into molecular changes leading to hepatopathy, *J. Biol. Chem.* 285 (2010) 10911–10923, <http://dx.doi.org/10.1074/jbc.M109.077610>.
- [14] J.-W. Park, W.-J. Park, Y. Kuperman, S. Boura-Halfon, Y. Pewzner-Jung, A.H. Futerman, Ablation of very long acyl chain sphingolipids causes hepatic insulin resistance in mice due to altered detergent-resistant membranes, *Hepatology* 57 (2013) 525–532, <http://dx.doi.org/10.1002/hep.26015>.
- [15] H. Zigdon, A. Kogot-Levin, J.-W. Park, R. Goldschmidt, S. Kelly, A.H. Merrill, et al., Ablation of ceramide synthase 2 causes chronic oxidative stress due to disruption of the mitochondrial respiratory chain, *J. Biol. Chem.* 288 (2013) 4947–4956, <http://dx.doi.org/10.1074/jbc.M112.402719>.
- [16] L.C. Silva, O. Ben-David, Y. Pewzner-Jung, E.L. Laviad, J. Stiban, S. Bandyopadhyay, et al., Ablation of ceramide synthase 2 strongly affects biophysical properties of membranes, *J. Lipid Res.* 53 (2012) 430–436, <http://dx.doi.org/10.1194/jlr.M022715>.
- [17] M. Ali, J. Fritsch, H. Zigdon, Y. Pewzner-Jung, S. Schütze, A.H. Futerman, Altering the sphingolipid acyl chain composition prevents LPS/GLN-mediated hepatic failure in mice by disrupting TNFR1 internalization, *Cell Death Dis.* 4 (2013) e929, <http://dx.doi.org/10.1038/cddis.2013.451>.
- [18] W.-J. Park, J.-W. Park, R. Erez-Roman, A. Kogot-Levin, J.R. Bame, B. Tirosh, et al., Protection of a ceramide synthase 2 null mouse from drug-induced liver injury: role of gap junction dysfunction and connexin 32 mislocalization, *J. Biol. Chem.* 288 (2013) 30904–30916, <http://dx.doi.org/10.1074/jbc.M112.448852>.
- [19] W.S. Lagakos, A.M. Gajda, L. Agellon, B. Binas, V. Choi, B. Mandap, et al., Different functions of intestinal and liver-type fatty acid-binding proteins in intestine and in whole body energy homeostasis, *Am. J. Physiol. Gastrointest. Liver Physiol.* 300 (2011) G803–G814, <http://dx.doi.org/10.1152/ajpgi.00229.2010>.
- [20] J. Storch, Y.X. Zhou, W.S. Lagakos, Metabolism of apical versus basolateral sn-2-monoacylglycerol and fatty acids in rodent small intestine, *J. Lipid Res.* 49 (2008) 1762–1769, <http://dx.doi.org/10.1194/jlr.M800116-JLR200>.
- [21] S.-H. Chon, J.D. Douglass, Y.X. Zhou, N. Malik, J.L. Dixon, A. Brinker, et al., Over-expression of monoacylglycerol lipase (MGL) in small intestine alters endocannabinoid levels and whole body energy balance, resulting in obesity, *PLoS ONE* 7 (2012) e43962, <http://dx.doi.org/10.1371/journal.pone.0043962>.
- [22] C.-L.E. Yen, M.-L. Cheong, C. Grueter, P. Zhou, J. Moriwaki, J.S. Wong, et al., Deficiency of the intestinal enzyme acyl CoA:monoacylglycerol acyltransferase-2 protects mice from metabolic disorders induced by high-fat feeding, *Nat. Med.* 15 (2009) 442–446, <http://dx.doi.org/10.1038/nm.1937>.
- [23] T.J. Alsted, L. Nybo, M. Schweiger, C. Fedelius, P. Jacobsen, R. Zimmermann, et al., Adipose triglyceride lipase in human skeletal muscle is upregulated by exercise training, *Am. J. Physiol. Endocrinol.* 296 (2008) E445–E453, <http://dx.doi.org/10.1152/ajpendo.90912.2008>.
- [24] M. Schweiger, R. Schreiber, G. Haemmerle, A. Lass, C. Fedelius, P. Jacobsen, et al., Adipose triglyceride lipase and hormone-sensitive lipase are the major enzymes in adipose tissue triacylglycerol catabolism, *J. Biol. Chem.* 281 (2006) 40236–40241, <http://dx.doi.org/10.1074/jbc.M608048200>.
- [25] R.A. Coleman, Diacylglycerol acyltransferase and monoacylglycerol acyltransferase from liver and intestine, *Methods Enzymol.* 209 (1992) 98–104.
- [26] M.C. Sullards, Y. Liu, Y. Chen, A.H. Merrill, Analysis of mammalian sphingolipids by liquid chromatography tandem mass spectrometry (LC-MS/MS) and tissue imaging mass spectrometry (TIMS), *Biochim. Biophys. Acta* 1811 (2011) 838–853, <http://dx.doi.org/10.1016/j.bbaliip.2011.06.027>.
- [27] R.L. Shaner, J.C. Allegood, H. Park, E. Wang, S. Kelly, C.A. Haynes, et al., Quantitative analysis of sphingolipids for lipidomics using triple quadrupole and quadrupole linear ion trap mass spectrometers, *J. Lipid Res.* 50 (2009) 1692–1707, <http://dx.doi.org/10.1194/jlr.D800051-JLR200>.
- [28] E.L. Laviad, L. Albee, I. Pankova-Kholmiansky, S. Epstein, H. Park, A.H. Merrill, et al., Characterization of ceramide synthase 2: tissue distribution, substrate specificity, and inhibition by sphingosine 1-phosphate, *J. Biol. Chem.* 283 (2008) 5677–5684, <http://dx.doi.org/10.1074/jbc.M707386200>.
- [29] B.G. Bhat, P. Wang, R.A. Coleman, Sphingosine inhibits rat hepatic monoacylglycerol acyltransferase in Triton X-100 mixed micelles and isolated hepatocytes, *Biochemistry* 34 (1995) 11237–11244.
- [30] J. Storch, B. Corsico, The emerging functions and mechanisms of mammalian fatty acid-binding proteins, *Annu. Rev. Nutr.* 28 (2008) 73–95, <http://dx.doi.org/10.1146/annurev.nutr.27.061406.093710>.
- [31] T.D. Mullen, S. Spassieva, R.W. Jenkins, K. Kitatani, J. Bielawski, Y.A. Hannun, et al., Selective knockdown of ceramide synthases reveals complex interregulation of sphingolipid metabolism, *J. Lipid Res.* 52 (2011) 68–77, <http://dx.doi.org/10.1194/jlr.M009142>.
- [32] G. Hajnóczky, E. Gao, T. Nomura, J.B. Hoek, A.P. Thomas, Multiple mechanisms by which protein kinase A potentiates inositol 1,4,5-trisphosphate-induced Ca<sup>2+</sup> mobilization in permeabilized hepatocytes, *Biochem. J.* 293 (Pt 2) (1993) 413–422.
- [33] K. Richter, M. Nessler, P. Lichter, Experimental evidence for the influence of molecular crowding on nuclear architecture, *J. Cell Sci.* 120 (2007) 1673–1680, <http://dx.doi.org/10.1242/jcs.03440>.
- [34] C.M. Harmon, N.A. Abumrad, Binding of sulfosuccinimidyl fatty acids to adipocyte membrane proteins: isolation and amino-terminal sequence of an 88-kD protein implicated in transport of long-chain fatty acids, *J. Membr. Biol.* 133 (1993) 43–49.
- [35] S.L.M. Coort, J. Willems, W.A. Coumans, G.J. van der Vusse, A. Bonen, J.F.C. Glatz, et al., Sulfo-N-succinimidyl esters of long chain fatty acids specifically inhibit fatty acid translocase (FAT/CD36)-mediated cellular fatty acid uptake, *Mol. Cell. Biochem.* 239 (2002) 213–219.
- [36] Y. Li, J. Dong, T. Ding, M.-S. Kuo, G. Cao, X.-C. Jiang, et al., Sphingomyelin synthase 2 activity and liver steatosis: an effect of ceramide-mediated peroxisome proliferator-activated receptor  $\gamma$ 2 suppression, *Arterioscler. Thromb. Vasc. Biol.* 33 (2013) 1513–1520, <http://dx.doi.org/10.1161/ATVBAHA.113.301498>.
- [37] T.E. Fox, M.C. Bewley, K.A. Unrath, M.M. Pedersen, R.E. Anderson, D.Y. Jung, et al., Circulating sphingolipid biomarkers in models of type 1 diabetes, *J. Lipid Res.* 52 (2011) 509–517, <http://dx.doi.org/10.1194/jlr.M010595>.
- [38] R. Cinar, G. Godlewski, J. Liu, J. Tam, T. Jourdan, B. Mukhopadhyay, et al., Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing de novo synthesis of long-chain ceramides, *Hepatology* 59 (2014) 143–153, <http://dx.doi.org/10.1002/hep.26606>.
- [39] J. He, J.H. Lee, M. Febbraio, W. Xie, The emerging roles of fatty acid translocase/CD36 and the aryl hydrocarbon receptor in fatty liver disease, *Exp. Biol. Med.* 236 (2011) 1116–1121, <http://dx.doi.org/10.1258/ebm.2011.011128>.
- [40] C.T. Coburn, F.F. Knapp, M. Febbraio, A.L. Beets, R.L. Silverstein, N.A. Abumrad, Defective uptake and utilization of long chain fatty acids in muscle and adipose tissues of CD36 knockout mice, *J. Biol. Chem.* 275 (2000) 32523–32529, <http://dx.doi.org/10.1074/jbc.M003826200>.
- [41] R.D. Clugston, J.J. Yuen, Y. Hu, N.A. Abumrad, P.D. Berk, I.J. Goldberg, et al., CD36-deficient mice are resistant to alcohol- and high-carbohydrate-induced hepatic steatosis, *J. Lipid Res.* 55 (2014) 239–246, <http://dx.doi.org/10.1194/jlr.M041863>.



- [42] D.P.Y. Koonen, R.L. Jacobs, M. Febbraio, M.E. Young, C.L.M. Soltys, H. Ong, et al., Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity, *Diabetes* 56 (2007) 2863–2871, <http://dx.doi.org/10.2337/db07-0907>.
- [43] M.E. Miquilena-Colina, E. Lima-Cabello, S. Sánchez-Campos, M.V. García-Mediavilla, M. Fernández-Bermejo, T. Lozano-Rodríguez, et al., Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C, *Gut* 60 (2011) 1394–1402, <http://dx.doi.org/10.1136/gut.2010.222844>.
- [44] J. Pohl, A. Ring, Ü. Korkmaz, R. Ehehalt, W. Stremmel, FAT/CD36-mediated long-chain fatty acid uptake in adipocytes requires plasma membrane rafts, *Mol. Biol. Cell* 16 (2005) 24–31.
- [45] J. Zhou, M. Febbraio, T. Wada, Y. Zhai, R. Kuruba, J. He, et al., Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis, *Gastroenterology* 134 (2008) 556–567, <http://dx.doi.org/10.1053/j.gastro.2007.11.037>.
- [46] N.A. Abumrad, M.R. El-Maghrabi, E.Z. Amri, E. Lopez, P.A. Grimaldi, Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36, *J. Biol. Chem.* 268 (1993) 17665–17668.
- [47] J.R. Goudriaan, M.A.M. den Boer, P.C.N. Rensen, M. Febbraio, F. Kuipers, J.A. Romijn, et al., CD36 deficiency in mice impairs lipoprotein lipase-mediated triglyceride clearance, *J. Lipid Res.* 46 (2005) 2175–2181, <http://dx.doi.org/10.1194/jlr.M500112-JLR200>.
- [48] M.K. Brawer, G.E. Austin, K.J. Lewin, Focal fatty change of the liver, a hitherto poorly recognized entity, *Gastroenterology* 78 (1980) 247–252.
- [49] E.K. Paulson, M.E. Baker, C.E. Spritzer, R.A. Leder, D.J. Gulliver, W.C. Meyers, Focal fatty infiltration: a cause of nontumorous defects in the left hepatic lobe during CT arterial portography, *J. Comput. Assist. Tomogr.* 17 (1993) 590–595.
- [50] L. van der Westhuizen, W.C.A. Gelderblom, G.S. Shephard, S. Swanevelder, Disruption of sphingolipid biosynthesis in hepatocyte nodules: selective proliferative stimulus induced by fumonisin B1, *Toxicology* 200 (2004) 69–75, <http://dx.doi.org/10.1016/j.tox.2004.03.011>.
- [51] S. Lumlertdacha, R.T. Lovell, R.A. Shelby, S.D. Lenz, B.W. Kempainen, Growth, hematology, and histopathology of channel catfish, *Ictalurus punctatus*, fed toxins from *Fusarium moniliforme*, *Aquaculture* 130 (1995) 201–218.
- [52] G. Musso, R. Gambino, M. Cassader, Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD), *Prog. Lipid Res.* 48 (2009) 1–26, <http://dx.doi.org/10.1016/j.plipres.2008.08.001>.

## Update

### **BBA - Molecular and Cell Biology of Lipids**

Volume 1851, Issue 7, July 2015, Page 996


DOI: <https://doi.org/10.1016/j.bbalip.2015.03.002>



Contents lists available at ScienceDirect

## Biochimica et Biophysica Acta

journal homepage: [www.elsevier.com/locate/bbalip](http://www.elsevier.com/locate/bbalip)



### Corrigendum

## Corrigendum to “Hepatic fatty acid uptake is regulated by the sphingolipid acyl chain length” [Mol. Cell Biol. Lipids 1841(12) (2014) 1754–1766]



Woo-Jae Park<sup>a,b</sup>, Joo-Won Park<sup>a,c</sup>, Alfred H. Merrill Jr.<sup>d</sup>, Judith Storch<sup>e</sup>,  
Yael Pewzner-Jung<sup>a</sup>, Anthony H. Futerman<sup>a,\*</sup>

<sup>a</sup> Department of Biological Chemistry, Weizmann Institute of Science, Rehovot 76100, Israel

<sup>b</sup> Department of Biochemistry, School of Medicine, Gachon University, Incheon 406-799, South Korea

<sup>c</sup> Department of Biochemistry, School of Medicine, Ewha Womans University, Seoul 158-710, South Korea

<sup>d</sup> School of Biology and Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA 30332-0230, USA

<sup>e</sup> Department of Nutritional Sciences, Rutgers Center for Lipid Research, Rutgers University, New Brunswick, NJ 08901, USA

The authors would like to add the following information in the Acknowledgments section:  
This work was supported in part by the National Institutes of Health Grant GM076217.  
The authors would like to apologize for any inconvenience caused.

DOI of original article: <http://dx.doi.org/10.1016/j.bbalip.2014.09.009>.

\* Corresponding author.

E-mail address: [tony.futerman@weizmann.ac.il](mailto:tony.futerman@weizmann.ac.il) (A.H. Futerman).

<http://dx.doi.org/10.1016/j.bbalip.2015.03.002>

1388-1981/© 2015 Elsevier B.V. All rights reserved.